Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevoflurane vs Propofol Sedation in Moderate ARDS
NCT05259631Phase 3Suspended
- Sponsor
- Negovsky Research Institute of General Reanimatology
- Start
- Mar 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sevoflurane in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Negovsky Research Institute of General Reanimatology. Primary endpoint: PaO2/FiO2 ratio at day 2. Started Mar 2022; status: suspended.
02
Drugs
sevoflurane
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05259631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259631.